JMP Securities reiterated their market perform rating on shares of Inhibrx (NASDAQ:INBX - Free Report) in a report issued on Wednesday,Benzinga reports.
Inhibrx Stock Performance
INBX traded down $0.51 on Wednesday, hitting $13.09. The company had a trading volume of 152,668 shares, compared to its average volume of 85,626. Inhibrx has a 52-week low of $10.80 and a 52-week high of $18.95. The stock has a fifty day simple moving average of $14.64 and a 200-day simple moving average of $14.66.
Insider Buying and Selling
In other Inhibrx news, Director Jon Faiz Kayyem bought 69,686 shares of the stock in a transaction dated Tuesday, November 19th. The stock was purchased at an average cost of $14.23 per share, for a total transaction of $991,631.78. Following the completion of the acquisition, the director now owns 51,093 shares of the company's stock, valued at approximately $727,053.39. This trade represents a -374.80 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 22.20% of the stock is owned by insiders.
Institutional Investors Weigh In On Inhibrx
An institutional investor recently bought a new position in Inhibrx stock. Exchange Traded Concepts LLC acquired a new stake in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 9,608 shares of the company's stock, valued at approximately $148,000. Exchange Traded Concepts LLC owned about 0.07% of Inhibrx as of its most recent filing with the SEC. 82.46% of the stock is currently owned by institutional investors.
About Inhibrx
(
Get Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Featured Stories
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
